Genetic susceptibility to angiotensin-converting enzyme-inhibitor induced angioedema: A systematic review and evaluation of methodological approaches
Open Access
- 11 November 2019
- journal article
- review article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (11) , e0224858
Abstract
Angiotensin-converting enzyme (ACE) converts angiotensin I to angiotensin II which causes vasoconstriction. ACE inhibitors reduce blood pressure by inhibiting ACE. A well-known adverse drug reaction to ACE inhibitors is ACE inhibitor-induced angioedema (ACEi-AE). Angioedema is a swelling of skin and mucosa, which can be fatal if the airway is compromised. We have performed a systematic review of the evidence suggesting that genetic polymorphisms are associated with ACEi-AE and evaluated the methodological approaches of the included studies. The Cochrane Database of Systematic Reviews, Google Scholar, and PubMed were searched. Studies investigating the association between genetic markers and ACEi-AE were included. The Q-genie tool was used to evaluate the quality of the study methodologies. Seven studies were included. With the exception of one whole genome study, all of the included studies were candidate gene association studies. Study quality assessment scores ranged from 36 to 55. One study was found to be of good quality, suggesting that the detected associations may be unreliable. The inferior quality of some studies was due to poor organization, lack of analyses and missing information. Polymorphisms within XPEPNP2, BDKRB2–9/+ 9 and neprilysin genes, were reported to be associated with increased risk of ACEi-AE. However, due to low quality, these associations need to be confirmed in larger studies.Keywords
This publication has 30 references indexed in Scilit:
- Factor XII–independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and IIJournal of Allergy and Clinical Immunology, 2013
- Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedemaPharmacogenetics and Genomics, 2010
- The plasma bradykinin-forming pathways and its interrelationships with complementMolecular Immunology, 2010
- Potential genetic risk factors in angiotensin-converting enzyme-inhibitor-induced angio-oedemaBritish Journal of Clinical Pharmacology, 2010
- The role of ace gene polymorphism in the development of angioedema secondary to angiotensin converting enzyme inhibitors and angiotensin II receptor blockersAllergologia et Immunopathologia, 2008
- Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated AngioedemaHypertension, 2008
- Nonallergic angioedema: role of bradykininAllergy, 2007
- A Variant in XPNPEP2 Is Associated with Angioedema Induced by Angiotensin I–Converting Enzyme InhibitorsThe American Journal of Human Genetics, 2005
- The Effect of Acute Angiotensin-Converting Enzyme and Neutral Endopeptidase 24.11 Inhibition on Plasma Extravasation in the RatThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Metabolism of substance P and neurokinin A by human vascular endothelium and smooth musclePeptides, 1994